News archives

Home > News archives

NBHL will present as a guest speaker in Research Xchange Seminar Tokyo 2019

May 13,2019 -- Updated 19:02 +0900 (GMT)

“Research Xchange Seminar Tokyo 2019: Cell analysis to accelerate oncology/immuno-oncology” will be held on May 23rd, 2019. Kiyoshi Takayama (President, NBHL) will make a presentation on “Screening of GPCR-targeted monoclonal antibodies using iQue® Screener.”

For more information on this seminar, please visit

https://sartorius-if.smktg.jp/public/seminar/view/17

NBHL will attend BIO-Europe Spring 2019 in Vienna, Austria.

Mar 25,2019 -- Updated 09:43 +0900 (GMT)

NBHL will be at “BIO-Europe Spring 2019” to be held in Vienna, Austria, from March 25th to 27th, 2019. Our Business Development team will attend this exciting event and would like to meet you there.

For more information on this event, please visit https://ebdgroup.knect365.com/bioeurope-spring/

NBHL to present at PHAR-EAST 2019 in Sentosa Island, Singapore

Mar 14,2019 -- Updated 11:30 +0900 (GMT)

NBHL will be at PHAR-EAST 2019 (Asia’s Pharma & Biotech Festival) to be held in Sentosa Island, Singapore, from March 18th to 20th, 2019. Kiyoshi Takayama (President, NBHL) will make a short presentation on “MoGRAA® discovery engine”, our technology platform for the discovery of functional monoclonal antibody therapeutics targeting GPCRs and our antibody pipeline at Biotech Pitch in the event.

For more information on this event, please visit https://www.terrapinn.com/exhibition/phar-east/speaker-kiyoshi-TAKAYAMA.stm

NBHL will attend BIO-Europe 2018 in Copenhagen, Denmark.

Oct 23,2018 -- Updated 17:18 +0900 (GMT)

NBHL will be at “BIO-Europe 2018” to be held in Copenhagen, Denmark, from November 5th to 7th, 2018. Kiyoshi Takayama (CEO, NBHL) will attend this exciting event and would like to meet you there.

 

For more information on this event, please visit https://ebdgroup.knect365.com/bioeurope/

NBHL to present at the HUMAN ANTIBODIES & HYBRIDOMAS 2018 Conference in Riga, Latvia

Oct 16,2018 -- Updated 13:32 +0900 (GMT)

Kiyoshi Takayama (CEO, NBHL) will give a presentation at the HUMAN ANTIBODIES & HYBRIDOMAS 2018 Conference to be held in Riga, Latvia, from October 22nd to 24th, 2018.

[Date of presentation]

October 23rd, 2018

[Venue]

Pullman Riga Old Town Hotel, Riga, Latvia

[Session]

Session 5: Therapeutic targets and antibody immunotherapy

[Presentation title]

MoGRAA® discovery engine can expand the drug targets of therapeutic mAb

[URL]

http://www.meetingsmanagement.co.uk

NBHL will be present at BioJapan 2018 in Yokohama, Japan

Oct 7,2018 -- Updated 16:29 +0900 (GMT)

NBHL will have a panel exhibition at B-02 (in Hokkaido BIO Technology Cluster booth) in “BioJapan 2018” to be held in Pacifico Yokohama, Japan, from October 10th to 12th, 2018. Kiyoshi Takayama (CEO, NBHL) will make a short presentation on “MoGRAA® discovery engine”, our technology platform for the discovery of functional monoclonal antibody therapeutics targeting GPCRs. This presentation is scheduled at Stage B of Exhibitor’s Presentation from 14:00 to 14:10 on October 10th.

For more information on this event, please visit https://www.ics-expo.jp/biojapan/en/

Closing of the funding to boost R&D

Aug 28,2018 -- Updated 18:53 +0900 (GMT)

Sapporo, Japan, May 31, 2018 – NB Health Laboratory Co. Ltd. (Head Office: Kita-Ku, Sapporo; President: Kiyoshi Takayama, Ph.D.) today announced that NBHL has raised ¥360 million in an equity funding round through Fast Track Initiative Fund II, L.P., ANNIVERSAIRE HOLDINGS INC., SMBC Venture Capital Fund IV, L.P. and Hokkaido Seichou Kigyou Fund, L.P. The funds will be used to boost the development of NBHL GPCR mAb technology (MoGRAA® discovery engine) and strengthen the corporate system.

NBHL’s article “MoGRAA® discovery engine” published in journal of PSJ

Mar 9,2018 -- Updated 10:31 +0900 (GMT)

NBHL’s article “MoGRAA® discovery engine for the discovery of functional mAb therapeutics targeting GPCRs” has been published in Farumashia, the journal of The Pharmaceutical Society of Japan.
Farumashia Vol.54 No.3: 246-248 (2018) [in Japanese]

Closing of the funding to accelerate R&D

Nov 2,2016 -- Updated 22:48 +0900 (GMT)

Sapporo, Japan, Oct. 28, 2016 – NB Health Laboratory Co. Ltd. (Head Office: Kita-Ku, Sapporo; President: Kiyoshi Takayama, Ph.D.) today announced that NBHL has raised ¥200 million in an equity funding round through Fast Track Initiative Fund II, L.P.
managed by Fast Track Initiative, Inc. (Head Office: Bunkyo-Ku Tokyo; CEO Hiromichi Kimura, PhD). The funds will be used to accelerate development of NBHL original bio medicine.

NBHL will participate in “BioJapan 2016” in Yokohama.

Sep 21,2016 -- Updated 17:32 +0900 (GMT)

NBHL will hold a panel exhibition at A-35 (in Hokkaido Bio Cluster booth)  in “BioJapan 2016”, held from October 12th to 14th, 2016 in Pacifico Yokohama, Japan. We will present “MoGRAA™ discovery engine”, our technology platform for GPCR antibody production.

次へ »